ENOB Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 aug 2023 @ 21:58):

Stats
Dagens volum	87 289.00
Gjennomsnittsvolum	254 603
Markedsverdi	45.38M
EPS	$-698 421 ( 2023-08-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.344
ATR14	$0.193 (7.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-23	Miller Avram	Buy	1 000 000	Common Stock
2023-10-23	Miller Avram	Buy	27 147	Option to purchase shares of common stock
2023-10-11	Miller Avram	Buy	0
2023-10-04	Hendriks Ruud	Buy	16 129	Option to purchase shares of common stock
2023-10-04	Boeren Leni	Buy	16 129	Option to purchase shares of common stock

INSIDER POWER
98.17
Last 80 transactions
Buy: 35 900 381 \| Sell: 26 846 213

Volum Korrelasjon

Lang: 0.11 (neutral)

Kort: -0.07 (neutral)

Signal:(77.816) Neutral

Enochian Biosciences Inc Korrelasjon

10 Mest positive korrelasjoner
UK	0.894
GAINL	0.893
MRACW	0.892
AYLA	0.891
KBSF	0.887
GRNV	0.885
ISNS	0.884
BIOL	0.879
VIH	0.874
MDWT	0.868

10 Mest negative korrelasjoner
BOCH	-0.92
ALPN	-0.918
BNIXU	-0.911
SGH	-0.904
NXGL	-0.903
ELTK	-0.902
AMAT	-0.892
ULTA	-0.891
MOTNU	-0.889
PEBK	-0.885

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Enochian Biosciences Inc Korrelasjon - Valuta/Råvare

-0.36
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.40
( neutral )

-0.53
( weak negative )

-0.32
( neutral )

Enochian Biosciences Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-705 302

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-705 302

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.16

Financial Reports:

No articles found.

Enochian Biosciences Inc

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.